STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Alzamend Neuro ownership update: Ault group at ~8%

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Alzamend Neuro (ALZN) filed Amendment No. 10 to Schedule 13D, updating beneficial ownership by Milton C. Ault III and affiliated entities. The filing is based on 3,539,861 shares outstanding as of October 2, 2025.

Mr. Ault may be deemed to beneficially own 306,321 shares, or approximately 8.0% of the class, including direct holdings and shares attributable through affiliates. Hyperscale Data, Inc. reports 293,349 shares (approximately 7.7%), and Ault Lending, LLC reports 293,337 shares (approximately 7.7%). These positions include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending, plus smaller direct common holdings across affiliates.

The filing details voting and dispositive powers across entities and notes that no transactions in the past 60 days occurred other than those listed in an exhibit.

Positive

  • None.

Negative

  • None.

Insights

Ownership update shows Ault-related entities at ~8% of ALZN.

The amendment reports consolidated beneficial ownership tied to Milton C. Ault III and affiliates, anchored to October 2, 2025 outstanding shares. The positions blend direct common shares with derivative securities, including Series B Convertible Preferred Stock and currently exercisable warrants.

Concentration near the 5% reporting threshold is already exceeded, with Mr. Ault at 8.0% and key affiliates at 7.7%. Voting and dispositive power is split between sole and shared, reflecting holdings across entities.

Actual market impact depends on holder decisions and any conversions or exercises permitted by the instruments. Subsequent filings may provide updated ownership if positions change or derivatives are exercised.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Sole voting and dispositive power represents shares of Common Stock. Shared voting and dispositive power represents (i) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (ii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, (iii) 8,260 shares of Common Stock held by Ault Lending, LLC, (iv) 11,068 shares of Common Stock held by Ault Life Sciences, Inc., (v) 61 shares of Common Stock held by Ault Life Sciences Fund, LLC, and (vi) 12 shares of Common Stock underlying currently exercisable warrants held by Hyperscale Data, Inc.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 3,333 shares of Common Stock and (ii) 185 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 615 shares of Common Stock and (ii) 1,111 shares of Common Stock underlying stock options currently exercisable or exercisable within 60 days.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 12 shares of Common Stock underlying currently exercisable warrants held by it, (ii) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock held by Ault Lending, LLC, (iii) 23,334 shares of Common Stock underlying currently exercisable warrants held by Ault Lending, LLC, and (iv) 8,260 shares of Common Stock held by Ault Lending, LLC.


SCHEDULE 13D




Comment for Type of Reporting Person:
Represents (i) 8,260 shares of Common Stock, (ii) 261,743 shares of Common Stock underlying shares of Series B Convertible Preferred Stock and (iii) 23,334 shares of Common Stock underlying currently exercisable warrants.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


MILTON C. AULT, III
Signature:/s/ Milton C. Ault, III
Name/Title:Individual
Date:10/03/2025
WILLIAM B. HORNE
Signature:/s/ William B. Horne
Name/Title:Individual
Date:10/03/2025
HENRY C.W. NISSER
Signature:/s/ Henry C. Nisser
Name/Title:Individual
Date:10/03/2025
KENNETH S. CRAGUN
Signature:/s/ Kenneth S. Cragun
Name/Title:Individual
Date:10/03/2025
DAVID J. KATZOFF
Signature:/s/ David J. Katzoff
Name/Title:Individual
Date:10/03/2025
HYPERSCALE DATA, INC.
Signature:/s/ Milton C. Ault, III
Name/Title:Executive Chairman
Date:10/03/2025
AULT LENDING, LLC
Signature:/s/ David J. Katzoff
Name/Title:Manager
Date:10/03/2025
AULT LIFE SCIENCES, INC.
Signature:/s/ Milton C. Ault, III
Name/Title:Chief Executive Officer
Date:10/03/2025
AULT LIFE SCIENCES FUND, LLC
Signature:/s/ Milton C. Ault, III
Name/Title:Managing Member
Date:10/03/2025

FAQ

What stake in ALZN does Milton C. Ault III report in this 13D/A?

He may be deemed to beneficially own 306,321 shares, or approximately 8.0% of Alzamend Neuro’s common stock.

How many ALZN shares were outstanding for the ownership calculations?

The filing uses 3,539,861 shares outstanding as of October 2, 2025.

What do Hyperscale Data and Ault Lending report owning in ALZN?

Hyperscale Data reports 293,349 shares (~7.7%); Ault Lending reports 293,337 shares (~7.7%).

Which derivative securities are included in the reported ALZN ownership?

Holdings include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending.

Did the reporting persons trade ALZN in the last 60 days?

They state no transactions in the past 60 days except as set forth in Exhibit 1.

Who else is listed and what are their ALZN stakes?

William B. Horne: 3,518 shares (~0.1%); Henry C.W. Nisser: 926 shares; Kenneth S. Cragun: 1,111 shares; David J. Katzoff: 1,726 shares.
Alzamend Neuro Inc

NASDAQ:ALZN

ALZN Rankings

ALZN Latest News

ALZN Latest SEC Filings

ALZN Stock Data

8.33M
3.72M
0.81%
0.07%
4.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
ATLANTA